Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ebola broadly neutralizing antibody cocktail
- Development stage
- Preclinical
- Lead developer
- Eliteimmune
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ebola broadly neutralizing antibody cocktail (also known as IBT-T02) is a combination of two broadly neutralizing monoclonal antibodies, FVM04 and CA45, designed for the treatment and prevention of Ebolavirus disease. The cocktail targets highly conserved, non-overlapping epitopes on the Ebolavirus glycoprotein (GP), providing broad-spectrum protection against multiple pathogenic species of the genus *Orthoebolavirus*, including Ebola virus (EBOV), Sudan virus (SUDV), and Bundibugyo virus (BDBV). Developed by Eliteimmune in collaboration with Integrated Biotherapeutics and Emergent BioSolutions, the cocktail has demonstrated complete protection and therapeutic efficacy in various animal models, including mice, guinea pigs, ferrets, and non-human primates. It is currently in preclinical development, with Phase 1 clinical trial preparations underway.
- Other names
- CA45 + FVM04FVM04 + CA45Pan-Ebola antibody cocktailPan-Ebolavirus antibody cocktail
02
Targets
Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on Ebola broadly neutralizing antibody cocktail.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ebola broadly neutralizing antibody cocktail.